21 May 2018 - - Cambridge, Massachusetts-based biotherapeutics company HiFiBiO Therapeutics has completed a USD 37.5m series B financing round, the company said.
The USD 37.5m series B financing was led by Sequoia China and LYFE Capital, and supported by existing series A investors, VI Ventures and Nest.Bio Ventures, as well as new investors, Legend Star Capital and Proxima Ventures.
HiFiBiO Therapeutics currently has more than 50 full-time employees operating out of three facilities in the US, France, and China. Both the laboratories in Cambridge, Mass. and Hangzhou, China are located within the Nest.Bio Ventures incubator facilities.
The company continues to establish multiple strategic partnerships with leading pharmaceutical and biotechnology companies to drive an innovative pipeline of antibody drugs that leverage its proprietary single-B-cell functional antibody discovery CelliGOTM platform.
HiFiBiO Therapeutics is mobilizing the human immune system to combat disease.
The company integrates deep-rooted biological expertise with comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.